You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Select search scope: search across all journals or within the current journal

Search this journal

Enter search terms…

Advanced search

Browse

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

All content on this site: Copyright © 2026 Sage Publications. All rights reserved. This website is technically supported and operated by China National Publications Import and Export (Group) Co., Ltd. 京ICP备09090397号-11

Comment: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19

Annals of Pharmacotherapy

Impact Factor: 2.3 / 5-Year Impact Factor: 2.7

Journal Homepage Submission guidelines

Restricted access

Letter

First published online September, 2023

Comment: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19

and

Volume 57, Issue 9

https://doi.org/10.1177/10600280221144932

Abstract

Get full access to this article

View all access options for this article.

References

Reid

Joyner

Lewis-Wolfson

TD.

Baricitinib versus tocilizumab for the treatment of moderate to severe COVID-19. Ann Pharmacother. Published online October 29, 2022. doi:10.1177/10600280221133376

Joob

Wiwanitkit

Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health. 2020;53(2):70. doi:10.3961/jpmph.20.065

Browse journal

Current issue OnlineFirst All issues